WILLARD DERE, M.D. - Corporate Board Profile

BIOMARIN PHARMACEUTICAL INC

Filing Date	Source Excerpt
2017-04-25	Willard Dere, M.D., 63, joined our Board in July 2016. Serves on Audit Committee and Science and Technology Committee. 2016 Independent Director Compensation: $648,705.
2018-04-24	Willard Dere, M.D., 64, July 2016, Professor of Internal Medicine, Executive Director of Personalized Health and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center
2019-04-23	Willard Dere, M.D., 65, July 2016, Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center
2020-04-14	Willard Dere, M.D., joined our Board in July 2016. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center.
2021-04-13	Willard Dere, M.D., joined our Board in July 2016. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. The CGN Committee is currently composed of four directors, each of whom is “independent” under the listing standards of Nasdaq. The members of the CGN Committee are Dr. Heron (Chair), Ms. Anderson, Dr. Dere and Dr. Pyott. The Science and Technology Committee is currently composed of six directors: Dr. Dere (Chair), Mr. Grey, Dr. Heron, Dr. Ho, Dr. Lawlis and Dr. Slamon. 2020 INDEPENDENT DIRECTOR COMPENSATION: Willard Dere, M.D. Fees Earned ($) 93,750 Stock Awards ($) 458,810 Total ($) 552,560.
2022-04-12	Willard Dere, M.D., 68, Director Since July 2016, Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Clinical and Translational Science Institute at the University of Utah Health Sciences Center. Chair of the Science and Technology Committee. 2021 INDEPENDENT DIRECTOR COMPENSATION: Fees Earned or Paid in Cash $93,750, Stock Awards $397,312, Total $491,062.
2023-04-11	Willard Dere, M.D. joined our Board in July 2016 and serves as Chair of the Science and Technology Committee. He is currently Professor Emeritus of Internal Medicine at the University of Utah and Chief Advisor to the CEO at Angitia Biopharmaceuticals, a private biopharmaceutical company. From November 2014 to June 2022, Dr. Dere served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Co-Director of the Utah Clinical and Translational Science Institute, Co-Director of the Center for Genomic Medicine, and the Associate Vice President for Research at the University of Utah Health Sciences Center. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as senior vice president of global development, and either the international or corporate chief medical officer from December 2004 to October 2014. Dr. Dere began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. Dr. Dere currently serves on the boards of Mersana Therapeutics, Inc. and Seres Therapeutics, Inc., both public biopharmaceutical companies, and Metagenomi, a privately-held biopharmaceutical company. In December 2017 Dr. Dere concluded his board service at Ocera Therapeutics, Inc., a public biopharmaceutical company, before its acquisition by Mallinckrodt PLC, and in 2022, he concluded his board service at Radius Health, which was acquired by a private equity firm. Dr. Dere also serves on the external advisory boards of the Utah Clinical and Translational Science Institute, and the Clinical and Translational Science Center at the University of California Davis School of Medicine. Since 2014, Dr. Dere has served on the Grants Working Group of the California Institute of Regenerative Medicine. Dr. Dere received a B.A. and an M.D. from the University of California, Davis, and trained in internal medicine at the University of Utah and in endocrinology/metabolism at the University of California at San Francisco.
2024-04-09	Willard Dere, M.D. joined our Board in July 2016 and serves as Chair of the Science and Technology Committee. He is currently Professor Emeritus of Internal Medicine at the University of Utah ... 2023 Independent Director Compensation ... Willard Dere, M.D. 95,000 Fees Earned or Paid in Cash, 385,438 Stock Awards, 480,438 Total.
2025-04-08	Willard Dere, M.D. joined our Board in July 2016 and serves as Chair of the Science and Technology Committee. He is Professor Emeritus of Internal Medicine at the University of Utah. 2024 Non-Employee Director Compensation: Willard Dere, M.D. received total compensation of $463,045.